深圳欣博盛生物科技有限公司 a1

Amyloid Beta Peptide 1-42 (HFIP treated) Monomers
品牌:Stressmarq
货号:SPR-485E 规格:500 µg 目录价:¥3402
产品详情
产品名称:
Amyloid Beta Peptide 1-42 (HFIP treated) Monomers
别名:
Abeta Protein, Abeta peptide, Amyloid beta peptide, Beta amyloid peptide, amyloid beta precursor protein peptide, APP
产品描述:
Human Synthetic Amyloid Beta Peptide 1-42 (HFIP treated)
反应种属:
Human
实验应用:
WB | In vivo Assay | In vitro Assay
纯化方式:
N/A
偶联:
No Tag
产品浓度:
N/A - dried peptide film
表达系统:
N/A
保存温度:
-80ºC
运输温度:
Blue Ice or 4ºC
预期分子量:
4.5 kDa
存储溶液:
Dry powder. See "Other Resources" for re-suspension instructions/protocol.
产地:
加拿大
功能与背景:
Our amyloid beta peptide 1-42 (Aβ42) is produced synthetically and treated with 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) prior to drying which breaks down pre-formed fibrils and monomerizes the peptide, as previously published (1,2). Upon resuspension in DMSO/dH2O, our Aβ42 presents as a monomeric peptide without fibrils when observed under TEM, AFM and on a Western Blot with an anti-amyloid beta antibody. In contrast to AB42 oligomer and fibril constructs, our Aβ42 monomers were not toxic to primary rat cortical neurons. In the brain, amyloid beta peptide (Aβ) is generated by protease cleavage of amyloid precursor protein (APP), which aggregates into oligomers, protofibrils, fibrils and ultimately plaques in neurodegenerative diseases. The accumulation of Aβ plaques in the brain is considered a hallmark of Alzheimer’s disease (AD), and most of the drugs tested for AD in the past 20 years have targeted amyloid beta accumulation (3). Soluble Aβ oligomers isolated from the brains of AD patients or those generated in vitro potently impaired synapse structure and function (4). Aβ oligomers generated in vitro were toxic to PC12 cells (2) and SH-SY5Y cells (5). Aβ was demonstrated to interact with tauopathies to affect neurodegeneration in AD patients (6) and accumulations of Aβ were shown to be associated with lower survival rates in Parkinson’s disease patients with dementia (7).
纯度:
>98%
在线留言
咨询类型
联系人
*
联系方式
*
单位名称
*
咨询内容
*